New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Actuate Therapeutics, Inc. (ACTU) vs Neuphoria Therapeutics Inc. (NEUP)

Actuate Therapeutics, Inc. and Neuphoria Therapeutics Inc. are both Biotechnology companies. Actuate Therapeutics, Inc. and Neuphoria Therapeutics Inc. are of similar size ($12.9M and $12.6M). Across the 8 metrics below, Neuphoria Therapeutics Inc. leads on 5 and Actuate Therapeutics, Inc. on 3.

Valuation

Metric ACTU NEUP Biotechnology median
P/E n/m n/m 8.49
P/S — 0.81 8.56
P/B n/m 0.54 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m 0.45 0.69
EV/Sales — (0.38) 8.00
Earnings yield (346.00%) (38.02%) (35.81%)
Free cash flow yield (302.29%) (76.18%) (25.41%)

Profitability

Metric ACTU NEUP Biotechnology median
Gross margin — — 70.18%
Operating margin — — 0.00%
Net margin — — 0.00%
Free cash flow margin — — 0.00%
Return on equity (364.70%) (27.63%) (51.58%)
Return on assets (176.44%) (18.26%) (45.91%)
Return on invested capital 0.00% (186.04%) 0.00%

Growth

Metric ACTU NEUP Biotechnology median
Revenue growth (TTM) — — 7.20%
EPS growth (last fiscal year) 67.48% (1,230.43%) 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric ACTU NEUP Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.73 18.05 4.79
Net debt to EBITDA 0.59 1.26 1.01

Dividend

Metric ACTU NEUP Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ACTU NEUP Biotechnology median
Market cap 12.91m 12.55m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack